Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

MERCK & CO., INC.

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Of Molecules & Medicine: Dr Maurice Hilleman ("The Father Of Modern Vaccines")

11/27/2020 | 01:10pm EST

As the development and possible approval of a vaccine for Covid-19 gathers momentum, we take a brief look at and reflect on the life of the American microbiologist and inventor Dr Maurice Hillemanwho specialised in vaccinology and is widely regarded as the 20th century's leading vaccinologist.

Dr Maurice Hilleman is sometimes referred to as “The father of modern vaccines” and last year marked one hundred years since his birth in Montana. However, outside of his chosen field and to the public at large, it would seem he remains relatively unknown despite his many and long lasting achievements.

During his career, Dr Hilleman developed over forty vaccines for humans and animals. He developed eight of the fourteen vaccines which are currently recommended in the US, including those for measles, mumps, hepatitis A and B, and chickenpox. He also played a significant role in the discovery of the cold producing adenoviruses.

Dr Hilleman started his career at E.R. Squibb & Sons (now Bristol-Myers Squibb) where he developed a vaccine against encephalitis B for use mainly for US troops during World War II. As chief of the Department of Respiratory Diseases at the Army Medical Center shortly after the war, Dr Hilleman discovered the generic changes that occur when the influenza virus mutates, known as shift and drift. Based on this discovery, he proposed a flu vaccination would be required on an annual basis. His swift action in 1957 meant that an outbreak of influenza in Hong Kong did not become a huge pandemic.

Dr Hilleman later joined Merck & Co where he developed, with co-workers, most of the forty animal and human vaccines with which he's credited. It was during his time at Merck that Dr Hilleman cultivated material from his daughter who had gone down with mumps and used it as the basis of the mumps vaccine. The “Jeryl Lynn” strain is still used today and currently used in the MMR vaccine which itself was the first vaccine approved incorporating multiple live virus strains. Dr Hilleman is reported as considering his work on hepatitis B as his greatest achievement which subsequently helped remove one of the most important obstacles facing organ transplantation.

Dr Hilleman earned some of the highest honours in his field including the National Medal of Science in 1988, the highest scientific honour given by the United States; and a special lifetime achievement award from the Children's Vaccine Initiative of the World Health Organisation in 1996. Dr Robert C. Gallo, who is best known for his work in co-discovering that HIV was the cause of AIDS and developed the HIV blood test, commented that if he had to name a person who had done more for the benefit of human health, with less recognition than anyone else, it would be Dr Hilleman1. Dr Anthony Fauci (Director of the National Institute of Allergy and Infectious Diseases), commented that “Hilleman is one of the true giants of science, medicine and public health in the 20th Century.” He went on to add that “One can say without hyperbole that Maurice has changed the world.” It is fair to say that vaccines are one of the greatest public health success stories in history and Dr Hilleman's legacy extends throughout the world.

Dr Hilleman is named as an inventor on numerous patents.  A few examples of his work and that of his co-workers are set out below:

US 3555149:                   Mumps vaccine and its preparation

US 3401084:                   Rubella vaccine and its preparation

US 3906092:                   Stimulation of antibody response

US 5021348:                     Attenuated hepatitis A virus

EP 0028987 B1: Process for in vivo culture of hepatitis B virus

Footnotes

1 Los Angeles Times, 13 April 2005

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mr David Rushton
Haseltine Lake Kempner LLP
Redcliff Quay
120 Redcliff Street, Bristol
Bristol
BS1 6HU
UK
Tel: 117910 3200
E-mail: NKoniakhina@hlk-ip.com
URL: www.hlk-ip.com/

© Mondaq Ltd, 2020 - Tel. +44 (0)20 8544 8300 - http://www.mondaq.com, source Business Briefing

All news about MERCK & CO., INC.
01/14Philips Partners with Merck to Develop Digital Systems for Fertility Treatmen..
MT
01/13Ligand Pharmaceuticals to Receive $1.5 Million Milestone Payment From Merck
MT
01/13MERCK : Confirms Agreement with UNICEF to Establish the World's First Global Ebo..
PU
01/12EISAI : To present data on lenvima monotherapy and in combination with keytruda ..
AQ
01/12MERCK : Gets FDA Priority Review of V114 Vaccine for Adults
DJ
01/12MERCK : Says FDA Accepts for Priority Review the Biologics License Application f..
MT
01/12MERCK : U.S. FDA Accepts for Priority Review the Biologics License Application f..
BU
01/11MERCK : to Hold Fourth-Quarter and Full-Year 2020 Sales and Earnings Conference ..
AQ
01/08Merck Create Advisory Panel to Address Company-Wide Digital Ethics
MT
01/08MERCK : to Hold Fourth-Quarter and Full-Year 2020 Sales and Earnings Conference ..
BU
More news
Financials (USD)
Sales 2020 48 200 M - -
Net income 2020 12 144 M - -
Net Debt 2020 15 159 M - -
P/E ratio 2020 17,6x
Yield 2020 2,94%
Capitalization 211 B 211 B -
EV / Sales 2020 4,69x
EV / Sales 2021 4,32x
Nbr of Employees 71 000
Free-Float 70,7%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | MarketScreener
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 22
Average target price 96,95 $
Last Close Price 83,38 $
Spread / Highest target 28,3%
Spread / Average Target 16,3%
Spread / Lowest Target 1,94%
EPS Revisions
Managers and Directors
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Sandy Tremps Vice President-R&D IT CIO
Thomas Henry Glocer Independent Director
Leslie A. Brun Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.1.93%210 954
JOHNSON & JOHNSON1.86%421 997
ROCHE HOLDING AG1.93%303 276
NOVARTIS AG1.65%217 178
PFIZER INC.-0.30%203 993
ABBVIE INC.3.15%195 120